Banner placeholder

Xenazine®

XenazineXENAZINE: 25 mg, scored tablet
(INN: tetrabenazine)

Xenazine® is indicated for the treatment of movement disorders associated with Huntington's chorea and hemiballismus.

Xenazine® was developed by Cambridge Laboratories (UK). EUSA Pharma holds an exclusive agreement for the distribution of Xenazine® in France where it obtained a marketing authorization in France in July 2005.